Phio Pharmaceuticals (PHIO) Projected to Post Earnings on Wednesday

Posted by Defense World Staff on Aug 12th, 2025

Phio Pharmaceuticals (NASDAQ:PHIO – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Wednesday, August 13th. Analysts expect Phio Pharmaceuticals to post earnings of ($0.36) per share for the quarter.

Phio Pharmaceuticals Trading Down 5.3%

NASDAQ PHIO opened at $2.13 on Tuesday. Phio Pharmaceuticals has a 12 month low of $0.97 and a 12 month high of $9.79. The stock has a market cap of $10.22 million, a P/E ratio of -0.33 and a beta of 0.86. The stock’s fifty day moving average price is $2.40 and its 200-day moving average price is $1.97.

Institutional Trading of Phio Pharmaceuticals

A hedge fund recently raised its stake in Phio Pharmaceuticals stock. Geode Capital Management LLC increased its holdings in shares of Phio Pharmaceuticals Corp. (NASDAQ:PHIO – Free Report) by 38.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 57,694 shares of the company’s stock after purchasing an additional 16,108 shares during the quarter. Geode Capital Management LLC owned approximately 1.20% of Phio Pharmaceuticals worth $136,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 57.31% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $14.00 price target on shares of Phio Pharmaceuticals in a report on Wednesday, June 25th.

Read Our Latest Stock Report on PHIO

About Phio Pharmaceuticals

(Get Free Report)

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.